Research progress of complications of polycystic ovary syndrome in obstetric department and mechanisms
-
摘要: 多囊卵巢综合征(PCOS)是体内激素水平改变导致的一种内分泌疾病, 困扰PCOS患者多年的不孕难题现已逐渐得到解决，但相关产科并发症的发生也随之逐渐增多。目前, PCOS患者妊娠高血压综合征、妊娠糖尿病、先兆流产等产科并发症方面的研究已取得一定进展。本文对PCOS产科并发症及其机制的研究进展进行系统性综述，以期为PCOS的临床诊治提供参考。Abstract: Polycystic ovary syndrome (PCOS) is an endocrine disease caused by changes in hormone levels in the body. The problem of infertility in PCOS patients that has been plagued for many years is gradually solved, and the obstetric complications are gradually increasing. some progress has made in researches for PCOS patients with gestational hypertension, gestational diabetes, and threatened abortion research. The article made a systematic review of the latest researches on obstetric complications of PCOS and its mechanism in order to provide reference for clinical diagnosis and treatment of PCOS.
-
-
[1] BALEN A H, MORLEY L C, MISSO M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance[J]. Hum Reprod Update, 2016, 22(6): 687-708. doi: 10.1093/humupd/dmw025
[2] TAY C T, JOHAM A E, HIAM D S, et al. Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: an overview of systematic reviews[J]. Clin Endocrinol, 2018, 89(5): 535-553. doi: 10.1111/cen.13753
[3] GADALLA M A, NORMAN R J, TAY C T, et al. Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome: an overview of systematic reviews[J]. Int J Fertil Steril, 2020, 13(4): 257-270.
[4] ANDREA D, FAUSER B C J M. Renaming PCOS: a two-state solution[J]. J Clin Endocrinol Metab, 2013, 98(11): 4325-4328. doi: 10.1210/jc.2013-2040
[5] TEEDE H J, MISSO M L, COSTELLO M F, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Clin Endocrinol, 2018, 89(3): 251-268. doi: 10.1111/cen.13795
[6] 符平, 吴文萃. 孕早期胎儿颈项透明层厚度的超声测量价值及与不良妊娠结局的关系[J]. 实用临床医药杂志, 2021, 25(15): 93-97. doi: 10.7619/jcmp.20211030 [7] PALOMBA S, FALBO A, RUSSO T, et al. Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes[J]. Fertil Steril, 2010, 94(5): 1805-1811. doi: 10.1016/j.fertnstert.2009.10.043
[8] LOUWERS Y V, LAVEN J S E. Characteristics of polycystic ovary syndrome throughout life[J]. Ther Adv Reproductive Heal, 2020, 18(14): 2633-2638.
[9] 李扬璐, 阮祥燕, MUECK A O. 多囊卵巢综合征对妊娠结局的影响研究进展[J]. 首都医科大学学报, 2016, 37(4): 449-453. doi: 10.3969/j.issn.1006-7795.2016.04.007 [10] NAVER K V, GRINSTED J, LARSEN S O, et al. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia[J]. BJOG, 2014, 121(5): 575-581. doi: 10.1111/1471-0528.12558
[11] PALOMBA S, FALBO A, CHIOSSI G, et al. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study[J]. J Clin Endocrinol Metab, 2014, 99(8): 2942-2951. doi: 10.1210/jc.2014-1214
[12] LI Y L, RUAN X Y, WANG H S, et al. Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment[J]. Fertil Steril, 2018, 109(4): 720-727. doi: 10.1016/j.fertnstert.2017.12.023
[13] 王婷婷, 付翰林, 陈立章, 等. 中国多囊卵巢综合征患者妊娠并发症发生率的Meta分析[J]. 中南大学学报: 医学版, 2017, 42(11): 1300-1310. doi: 10.11817/j.issn.1672-7347.2017.11.010 [14] VALDIMARSDOTTIR R, WIKSTRÖ M A K, KALLAK T K, et al. Pregnancy outcome in women with polycystic ovary syndrome in relation to second-trimester testosterone levels[J]. Reproductive Biomed Online, 2021, 42(1): 217-225. doi: 10.1016/j.rbmo.2020.09.019
[15] 王喆, 张颐. 卵巢癌内分泌治疗研究进展[J]. 实用临床医药杂志, 2021, 25(13): 115-118, 128. doi: 10.7619/jcmp.20211462 [16] 魏代敏, 张真真, 王泽, 等. 高雄激素对多囊卵巢综合征患者辅助生殖治疗妊娠后产科并发症的影响[J]. 中华妇产科杂志, 2018, 53(1): 18-22. doi: 10.3760/cma.j.issn.0529-567x.2018.01.005 [17] MORAN L J, NORMAN R J, TEEDE H J. Metabolic risk in PCOS: phenotype and adiposity impact[J]. Trends Endocrinol Metab TEM, 2015, 26(3): 136-143. doi: 10.1016/j.tem.2014.12.003
[18] BOOMSMA C M, EIJKEMANS M J C, HUGHES E G, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome[J]. Hum Reprod Update, 2006, 12(6): 673-683. doi: 10.1093/humupd/dml036
[19] KJERULFF L E, SANCHEZ-RAMOS L, DUFFY D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis[J]. Am J Obstet Gynecol, 2011, 204(6): 558. e1-558. e6. doi: 10.1016/j.ajog.2011.03.021
[20] BAHRI KHOMAMI M, BOYLE J A, TAY C T, et al. Polycystic ovary syndrome and adverse pregnancy outcomes: current state of knowledge, challenges and potential implications for practice[J]. Clin Endocrinol, 2018, 88(6): 761-769. doi: 10.1111/cen.13579
[21] KLEVEDAL C, TURKMEN S. Fetal-maternal outcomes and complications in pregnant women with polycystic ovary syndrome[J]. Minerva Ginecologica, 2017, 69(2): 141-149.
[22] NATHALIE R, HELLE K, LENA S, et al. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study[J]. BMJ Clin Res Ed, 2011, 343(7828): d6309.
[23] LEGRO R, BARNHART H, SCHLAFF W, et al. Clomiphene, metformin or both for infertility in the polycystic ovary syndrome[J]. N Engl J Med, 2007, 356(6): 551-566. doi: 10.1056/NEJMoa063971
[24] LAIRD M, THOMSON K, FENWICK M, et al. Androgen stimulates growth of mouse preantral follicles in vitro: interaction with follicle-stimulating hormone and with growth factors of the TGFβ superfamily[J]. Endocrinology, 2017, 158(4): 920-935. doi: 10.1210/en.2016-1538
[25] ISSAT T, NOWICKA M A, JAKIMIUK A J. Polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM) risk[J]. Ginekologia Polska, 2015, 86(5): 392-395. doi: 10.17772/gp/2429
[26] GOU B H, GUAN H M, BI Y X, et al. Gestational diabetes: weight gain during pregnancy and its relationship to pregnancy outcomes[J]. Chin Med J, 2019, 132(2): 154-160. doi: 10.1097/CM9.0000000000000036
[27] VANKY E, STRIDSKLEV S, HEIMSTAD R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study[J]. J Clin Endocrinol Metab, 2010, 95(12): E448-E455. doi: 10.1210/jc.2010-0853
[28] JOHAM A E, RANASINHA S, ZOUNGAS S, et al. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2014, 99(3): E447-E452. doi: 10.1210/jc.2013-2007
[29] KHAMBULE L, GEORGE J A. The role of inflammation in the development of GDM and the use of markers of inflammation in GDM screening[J]. Adv Exp Med Biol, 2019(1134): 217-242.
[30] FOROOZANFARD F, MOOSAVI S G A, MANSOURI F, et al. Obstetric and neonatal outcome in PCOS with gestational diabetes mellitus[J]. J Fam Reproductive Heal, 2014, 8(1): 7-12.
[31] 曾玲, 陈建丽, 林巧玲. 多囊卵巢综合征妊娠患者与非多囊卵巢综合征孕妇妊娠结局比较[J]. 临床医学工程, 2020, 27(5): 569-570. doi: 10.3969/j.issn.1674-4659.2020.05.0569 [32] PALOMBA S, RUSSO T, FALBO A, et al. Macroscopic and microscopic findings of the placenta in women with polycystic ovary syndrome[J]. Hum Reprod, 2013, 28(10): 2838-2847. doi: 10.1093/humrep/det250
[33] BENNETT S N, ALAN T T, JOHN O, et al. Assessing White's classification of pregestational diabetes in a contemporary diabetic population[J]. Obstet Gynecol, 2015, 125(5): 1217-1223. doi: 10.1097/AOG.0000000000000820
[34] NANETTE O, SONY S. Pregnancy outcomes after assisted human reproduction[J]. J Obstet Gynaecol Can JOGC, 2014, 36(1): 64-83. doi: 10.1016/S1701-2163(15)30685-X
[35] LØVVIK T S, WIKSTRÖM A K, NEOVIUS M, et al. Pregnancy and perinatal outcomes in women with polycystic ovary syndrome and twin births: a population-based cohort study[J]. BJOG, 2015, 122(10): 1295-1302. doi: 10.1111/1471-0528.13339
[36] REGAN L, OWEN E J, JACOBS H S. Hypersecretion of luteinising hormone, infertility, and miscarriage[J]. Lancet, 1990, 336(8724): 1141-1144. doi: 10.1016/0140-6736(90)92765-A
[37] WANG Y H, ZHAO X M, ZHAO H D, et al. Risks for gestational diabetes mellitus and pregnancy-induced hypertension are increased in polycystic ovary syndrome[J]. Biomed Res Int, 2013, 2013: 182582.
[38] MERVIEL P, JAMES P, BOUÉE S, et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies[J]. Reproductive Heal, 2021, 18(1): 13. doi: 10.1186/s12978-021-01073-3
[39] CHECA M A, REQUENA A, SALVADOR C, et al. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome[J]. Hum Reprod Update, 2005, 11(4): 375-390. doi: 10.1093/humupd/dmi015
[40] 高颖. 孕期增重对多囊卵巢综合征妊娠结局影响研究[J]. 中国实用妇科与产科杂志, 2019, 35(3): 352-354. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF201903027.htm [41] MALIQUEO M, LARA H E, SÁNCHEZ F, et al. Placental steroidogenesis in pregnant women with polycystic ovary syndrome[J]. Eur J Obstet Gynecol, 2013, 166(2): 151-155. doi: 10.1016/j.ejogrb.2012.10.015
[42] KAJIHARA T, TANAKA K, OGURO T, et al. Androgens modulate the morphological characteristics of human endometrial stromal cells decidualized in vitro[J]. Reproductive Sci Thousand Oaks Calif, 2014, 21(3): 372-380. doi: 10.1177/1933719113497280
[43] JOHAM A E, PALOMBA S, HART R. Polycystic ovary syndrome, obesity, and pregnancy[J]. Semin Reproductive Med, 2016, 34(2): 93-101. doi: 10.1055/s-0035-1571195
[44] DE LEO V, MUSACCHIO M C, CAPPELLI V, et al. Genetic, hormonal and metabolic aspects of PCOS: an update[J]. Reproductive Biol Endocrinol, 2016, 14(1): 38. doi: 10.1186/s12958-016-0173-x
[45] SYLWIA B, AGNIESZKA S. The pathogenesis and treatment of polycystic ovary syndrome: what's new?[J]. Adv Clin Exp Med Off Organ Wroclaw Med Univ, 2017, 26(2): 359-367.
[46] GOODMAN N F, COBIN R H, FUTTERWEIT W, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-PART2[J]. Endocr Pract, 2015, 21(12): 1415-1426. doi: 10.4158/EP15748.DSCPT2
[47] EVANTHIA D K, ANDREA D. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications[J]. Endocr Rev, 2012, 33(6): 981-1030. doi: 10.1210/er.2011-1034
[48] NANDI A, CHEN Z, PATEL R, et al. Polycystic ovary syndrome[J]. Endocrinol Metab Clin North Am, 2014, 43(1): 123-147. doi: 10.1016/j.ecl.2013.10.003
[49] MOGHETTI P. Insulin resistance and polycystic ovary syndrome[J]. Curr Pharm Des, 2016, 22(36): 5526-5534. doi: 10.2174/1381612822666160720155855
[50] BREMER A A, MILLER W L. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance[J]. Fertil Steril, 2008, 89(5): 1039-1048. doi: 10.1016/j.fertnstert.2008.02.091
[51] ALESSANDRA G, DANIELA L, CHIARA M, et al. Female infertility: which role for obesity?[J]. Int J Obes Suppl, 2019, 9(1): 65-72. doi: 10.1038/s41367-019-0009-1
[52] QI J, WANG W S, ZHU Q L, et al. Local cortisol elevation contributes to endometrial insulin resistance in polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2018, 103(7): 2457-2467. doi: 10.1210/jc.2017-02459
[53] JOSEPH S, BARAI R S, BHUJBALRAO R, et al. PCOSKB: a KnowledgeBase on genes, diseases, ontology terms and biochemical pathways associated with PolyCystic Ovary Syndrome[J]. Nucleic Acids Res, 2015, 44(D1): D1032-D1035.
[54] ORÓSTICA L, POBLETE C, ROMERO C, et al. Pro-inflammatory markers negatively regulate IRS1 in endometrial cells and endometrium from women with obesity and PCOS[J]. Reproductive Sci Thousand Oaks Calif, 2020, 27(1): 290-300. doi: 10.1007/s43032-019-00026-3
[55] WANG J, WU D C, GUO H, et al. Hyperandrogenemia and insulin resistance: the chief culprit of polycystic ovary syndrome[J]. Life Sci, 2019, 236: 116940. doi: 10.1016/j.lfs.2019.116940
[56] LI X, GUO Y R, LIN J F, et al. Combination of diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance[J]. J Cancer, 2014, 5(3): 173-181. doi: 10.7150/jca.8009
[57] PALOMBA S, RUSSO T, ORIO F, et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome[J]. Hum Reprod, 2005, 21(2): 457-465.
[58] PALOMBA S, PILTONEN T T, GIUDICE L C. Endometrial function in women with polycystic ovary syndrome: a comprehensive review[J]. Hum Reprod Update, 2021, 27(3): 584-618. doi: 10.1093/humupd/dmaa051
[59] UJVARI D, GRAELLS BRUGALLA C, HIRSCHBERG A L. Dihydrotestosterone potentiates insulin to up-regulate prokineticin-1 in decidualizing human endometrial stromal cells[J]. J Cell Mol Med, 2020, 24(5): 3242-3245. doi: 10.1111/jcmm.14923
[60] ZHANG L, LIAO Q P. Effects of testosterone and metformin on glucose metabolism in endometrium[J]. Fertil Steril, 2010, 93(7): 2295-2298. doi: 10.1016/j.fertnstert.2009.01.096
[61] ROSAS C, ORÓSTICA L, POBLETE C, et al. Hyperandrogenism decreases GRP78 protein level and glucose uptake in human endometrial stromal cells[J]. Reproductive Sci Thousand Oaks Calif, 2016, 23(6): 761-770. doi: 10.1177/1933719115618283
[62] SIMITSIDELLIS I, SAUNDERS P T K, GIBSON D A. Androgens and endometrium: new insights and new targets[J]. Mol Cell Endocrinol, 2018, 465: 48-60. doi: 10.1016/j.mce.2017.09.022
[63] GONG H, WU W Q, XU J J, et al. Flutamide ameliorates uterine decidualization and angiogenesis in the mouse hyperandrogenemia model during mid-pregnancy[J]. PLoS One, 2019, 14(5): e0217095. doi: 10.1371/journal.pone.0217095
[64] GONZALEZ D, THACKERAY H, LEWIS P D, et al. Loss of WT1 expression in the endometrium of infertile PCOS patients: a hyperandrogenic effect[J]. J Clin Endocrinol Metab, 2012, 97(3): 957-966. doi: 10.1210/jc.2011-2366
-
期刊类型引用(7)
1. 刘娟，王凤兰. 川崎病患儿冠状动脉病变的影响因素分析及预测模型构建. 国际医药卫生导报. 2025(01): 60-65 . 
百度学术
2. 刘威，张兰. 婴儿川崎病冠状动脉病变的临床特点及危险因素分析. 分子诊断与治疗杂志. 2025(01): 38-40+45 . 百度学术
3. 徐树红，姜军. 川崎病患儿冠脉病变发生的危险因素模型构建及分析. 医学理论与实践. 2024(13): 2290-2292 . 百度学术
4. 张春燕. 白细胞介素-6/白蛋白比值与川崎病患儿冠状动脉损害的相关性研究. 中国实用医刊. 2023(11): 16-20 . 百度学术
5. 高健，陈雨青. 川崎病患儿发生血管损伤的影响因素. 血管与腔内血管外科杂志. 2023(07): 846-849+863 . 百度学术
6. 田慧，郝晓燕，祁洁，李莉，郭瑞霞，尉志红. 儿童川崎病的危险因素分析及列线图模型构建. 中西医结合心脑血管病杂志. 2023(17): 3278-3280 . 百度学术
7. 张惠，张晓斌，陈俊义. 川崎病患儿急性期血脂水平与冠脉病变关系的研究. 中国卫生标准管理. 2023(24): 23-27 . 百度学术
其他类型引用(2)
计量
- 文章访问数: 198
- HTML全文浏览量: 120
- PDF下载量: 19
- 被引次数: 9
下载:
苏公网安备 32100302010246号
